2014

Reportlinker Adds Ophthalmic Therapeutic Drugs: Technologies and Global Markets

NEW YORK, May 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Ophthalmic Therapeutic Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0196569/Ophthalmic-Therapeutic-Drugs-Technologies-and-Global-Markets.html

THIS REPORT

Discussion of ophthalmology drug products for such diseases as wet and dry age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and dry-eye; therapeutics for other diseases examined via qualitative analysis include those for conjunctiva, scleritis, macular edema, Usher's syndrome, and uveitis

Analysis of market trends, with data for 2008, estimates for 2009, and projections of compound annual growth rates (CAGRs) through 2014

A focus on salient manufacturers, technologies, geographies, and factors influencing demand

Comprehensive company profiles.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 2

INTENDED AUDIENCE 3

INFORMATION SOURCES 4

RELATED BCC REPORTS 4

BCC ONLINE SERVICES 5

DISCLAIMER 5

Chapter-2: EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, 2008-2014 ($ MILLIONS) 7

EXECUTIVE SUMMARY (CONTINUED) 8

Chapter-3: OVERVIEW

HISTORY AND CURRENT STATE OF OPHTHALMOLOGY DISEASE 9

ESTABLISHED DRUG CLASSES IN OPHTHALMOLOGY 10

EMERGING DRUG CLASSES 10

VEGF-Trap Eye 10

Combination Therapies 10

COMPETITION BETWEEN VEGF INHIBITORS IN WET AMD 11

TABLE 1 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN: PREVIOUS AND EXPECTED 11

TABLE 1 (CONTINUED) 12

Expected Outcome of CATT trial: Avastin v. Lucentis 12

GENETIC SPECIFICATIONS OF OPHTHALMIC DISEASE 13

TABLE 2 SUMMARY OF KNOWN GENES INFLUENCING DISEASE 13

TABLE 2 (CONTINUED) 14

SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 14

TABLE 3 RECENTLY APPROVED DRUGS, 2009 14

TABLE 4 SUMMARY PIPELINE FORECAST, 2012-2014 15

Chapter-4: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

INDUSTRY STRUCTURE 16

MARKET CONCENTRATION AND PRICE SENSITIVITY 16

TABLE 5 COMPANY BY DISEASE CLASS, 2009 REVENUE ($ MILLIONS) 17

COMPETITIVE FACTORS 18

TABLE 6 LARGE REVENUE, BRANDED DRUG SALES COMING OFF PATENT, 2009 18

MARKET TRENDS 18

Demographics Offer Tremendous Long-run Opportunity 18

TABLE 7 REVENUE GROWTH OF OPHTHALMOLOGY AS COMPARED TO TOTAL PHARMACEUTICAL MARKET, 2005-2009 (% YEAR-OVER-YEAR REVENUE GROWTH) 19

An Increasingly Challenging Global Reimbursement Environment 19

Sustained Drug Delivery Is the Future of Retinal Care 20

Payment Structures Are Ever More Important to Revenue Uptake and Peak Sales. 20

Fundamental Patient Need: Blindness or Impaired Vision Are Among the Most Debilitating Diseases 21

Combination Therapies Promise Improved Therapeutic Response 21

Expansion of Prescription Therapies to Rural Communities 21

TABLE 8 NUMBER OF U.S. HOSPITALS PROVIDING OPHTHALMIC CARE 22

TABLE 9 NUMBER OF TRAINED, LICENSED, AND CERTIFIED OPHTHALMOLOGISTS 22

TABLE 10 MARKET REVENUE AND SHARE BY LEADING OPHTHALMIC PLAYERS, 2009 ($ MILLIONS/%) 23

TABLE 11 MARKET ANALYSIS BY DISEASE, 2008 AND 2009 ($ MILLIONS) 23

TABLE 12 LEADING OPHTHALMIC THERAPIES, TOTAL SEGMENT, 2009 ($ MILLIONS/%) 24

NOTABLE MERGERS, ACQUISITIONS AND TRANSACTIONS 24

Roche/Genentech 24

Alcon/Novartis 25

Transaction Summary 25

Proposed Terms of Purchase 25

Integration Challenges and Opportunities 26

Fovea/Sanofi-Aventis 26

Fovea/Sanofi-Aventis (Continued) 27

Chapter-5: MARKETS BY DISEASE

SUMMARY OF MARKET DYNAMICS 28

TABLE 13 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 ($ MILLIONS) 29

AMD 29

PATHOPHYSIOLOGY AND PATHOGENESIS 29

Pathophysiology and Pathogenesis (Continued) 30

TREATMENT AND MANAGEMENT 31

Wet AMD 31

Wet AMD (Continued) 32

Dry AMD 33

FORECAST EPIDEMIOLOGY 33

TABLE 14   GLOBAL FORECAST EPIDEMIOLOGY: WET AMD, PREVALENCE, THROUGH 2014 33

TABLE 15 WET AMD REVENUE, 2009 SUMMARY, 2008 AND 2009 ($ MILLIONS) 34

TABLE 16 WET AMD, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 34

TABLE 17 WET AMD REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 35

TABLE 18   GLOBAL FORECAST EPIDEMIOLOGY: DRY AMD, PREVALENCE, THROUGH 2014 35

GLAUCOMA 35

PATHOPHYSIOLOGY AND PATHOGENESIS 35

Pathophysiology and Pathogenesis (Continued) 36

TREATMENT AND MANAGEMENT 37

Xalatan 37

Cosopt 38

Travatan 39

Lumigan 39

Lumigan (Continued) 40

Prostaglandins Analysis: First Line Treatment for Glaucoma 41

GLAUCOMA MANAGEMENT STRATEGIES 41

Combination Therapies in Glaucoma Management 41

FORECAST EPIDEMIOLOGY 42

TABLE 19   GLOBAL FORECAST EPIDEMIOLOGY: GLAUCOMA, PREVALENCE, THROUGH 2014 42

TABLE 20 GLAUCOMA REVENUE, 2009 SUMMARY ($ MILLIONS) 43

TABLE 21 GLAUCOMA, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 43

TABLE 22 GLAUCOMA REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 44

DIABETIC RETINOPATHY 44

PATHOPHYSIOLOGY AND PATHOGENESIS 44

Pathophysiology and Pathogenesis (Continued) 45

TABLE 23 SUCCESSIVE STAGES OF DIABETIC RETINOPATHY 46

TREATMENT AND MANAGEMENT 46

Avastin 46

Arxxant 47

Iluvien 47

FORECAST EPIDEMIOLOGY 48

TABLE 24   GLOBAL FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, PREVALENCE, THROUGH 2014 48

DRY-EYE DISEASE 48

PATHOPHYSIOLOGY AND PATHOGENESIS 48

TREATMENT AND MANAGEMENT 49

Restasis 49

Hyalein 50

Regulatory Update for Dry-eye Disease 51

FORECAST EPIDEMIOLOGY 52

TABLE 25   GLOBAL FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, PREVALENCE, THROUGH 2014 52

TABLE 26 DRY-EYE DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS/%) 53

TABLE 27 DRY-EYE DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 53

TABLE 28 DRY-EYE DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 54

ALLERGIC DISEASES 54

TABLE 29 ALLERGIC DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS/%) 55

TABLE 30 ALLERGIC DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS/%) 55

TABLE 31 ALLERGIC DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 56

INFECTIOUS DISEASES 56

TABLE 32 INFECTIOUS DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS) 57

TABLE 33   INFECTIOUS DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 57

TABLE 34   INFECTIOUS DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 58

INFLAMMATORY DISEASE 58

TABLE 35 INFLAMMATORY DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS/%) 59

TABLE 36   INFLAMMATORY DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 60

TABLE 37 INFLAMMATORY DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 60

COMBINATION INFECTIOUS AND INFLAMMATORY DISEASE 60

TABLE 38   DUAL INFLAMMATORY AND INFECTIVE DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS) 61

TABLE 39 DUAL INFLAMMATORY AND INFECTIVE DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 62

TABLE 40 DUAL INFLAMMATORY AND INFECTIVE DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 62

OTHER OPHTHALMIC PRESCRIPTION TREATMENTS 62

ADDITIONAL DISEASES 62

Uveitis 62

Scleritis (Noninfectious and Infectious) 63

Usher Syndrome 64

Coat's Disease 64

Eales Disease 65

Corneal Abrasion 65

Fuchs' Endothelial Dystrophy 66

Hypertensive Retinopathy 66

Stargardt's Disease (Juvenile Macular Degeneration) 66

Thygeson's Superficial Punctate Keratopathy 67

Chapter-6: MARKETS BY GEOGRAPHY

SUMMARY 68

METHODOLOGY 68

MARKET SIZING DEFINITIONS 69

UNITED STATES 69

TABLE 41   FORECAST U.S. EPIDEMIOLOGY: WET AMD, THROUGH 2014 70

TABLE 42    FORECAST U.S. EPIDEMIOLOGY: DRY AMD, THROUGH 2014 70

TABLE 43 FORECAST U.S. EPIDEMIOLOGY: GLAUCOMA, THROUGH 2014 70

TABLE 44 FORECAST U.S. EPIDEMIOLOGY: DRY-EYE DISEASE, THROUGH 2014 71

TABLE 45    FORECAST U.S. EPIDEMIOLOGY: DIABETIC RETINOPATHY, THROUGH 2014 71

WESTERN EUROPE 71

TABLE 46   FORECAST EPIDEMIOLOGY: WET AMD IN WESTERN EUROPE, THROUGH 2014 72

TABLE 47   FORECAST EPIDEMIOLOGY: DRY AMD IN WESTERN EUROPE, THROUGH 2014 72

TABLE 48 FORECAST EPIDEMIOLOGY: GLAUCOMA IN WESTERN EUROPE, THROUGH 2014 73

TABLE 49 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN WESTERN EUROPE, THROUGH 2014 73

TABLE 50 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN WESTERN EUROPE, THROUGH 2014 73

JAPAN 73

TABLE 51 FORECAST EPIDEMIOLOGY: WET AMD IN JAPAN, THROUGH 2014 74

TABLE 52 FORECAST EPIDEMIOLOGY: DRY AMD IN JAPAN, THROUGH 2014 74

TABLE 53 FORECAST EPIDEMIOLOGY: GLAUCOMA IN JAPAN, THROUGH 2014 75

TABLE 54 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN JAPAN, THROUGH 2014 75

TABLE 55   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, THROUGH 2014 75

STRATEGIES TO ACCESS EMERGING MARKETS 75

STRATEGIES TO ACCESS EMERGING … (CONTINUED) 76

EMERGING MARKETS FORECAST 77

BRAZIL 77

MARKET OVERVIEW 77

REGULATORY CONSIDERATIONS 78

PATENT CONSIDERATIONS 78

TABLE 56 FORECAST EPIDEMIOLOGY: WET AMD IN BRAZIL, THROUGH 2014 78

TABLE 57   FORECAST EPIDEMIOLOGY: DRY AMD IN BRAZIL, THROUGH 2014 79

TABLE 58   FORECAST EPIDEMIOLOGY: GLAUCOMA, THROUGH 2014 79

TABLE 59 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN BRAZIL, THROUGH 2014 79

TABLE 60 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN BRAZIL, THROUGH 2014 80

CHINA 80

MARKET OVERVIEW 80

REGULATORY CONSIDERATIONS 80

PATENT CONSIDERATIONS 81

TABLE 61 FORECAST EPIDEMIOLOGY: WET AMD IN CHINA, THROUGH 2014 82

TABLE 62 FORECAST EPIDEMIOLOGY: DRY AMD IN CHINA, THROUGH 2014 82

TABLE 63 FORECAST EPIDEMIOLOGY: GLAUCOMA IN CHINA, THROUGH 2014 82

TABLE 64 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN CHINA, THROUGH 2014 83

TABLE 65 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN CHINA, THROUGH 2014 83

INDIA 83

MARKET OVERVIEW 83

REGULATORY CONSIDERATIONS 84

PATENT CONSIDERATIONS 84

TABLE 66 FORECAST EPIDEMIOLOGY: WET AMD IN INDIA, THROUGH 2014 85

TABLE 67 FORECAST EPIDEMIOLOGY: DRY AMD IN INDIA, THROUGH 2014 85

TABLE 68 FORECAST EPIDEMIOLOGY: GLAUCOMA IN INDIA, THROUGH 2014 85

TABLE 69 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN INDIA, THROUGH 2014 86

TABLE 70 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN INDIA, THROUGH 2014 86

RUSSIA 86

MARKET OVERVIEW 86

REGULATORY CONSIDERATIONS 87

PATENT CONSIDERATIONS 87

TABLE 71   FORECAST EPIDEMIOLOGY: WET AMD IN RUSSIA, THROUGH 2014 87

TABLE 72   FORECAST EPIDEMIOLOGY: DRY AMD IN RUSSIA, THROUGH 2014 88

TABLE 73 FORECAST EPIDEMIOLOGY: GLAUCOMA IN RUSSIA. THROUGH 2014 88

TABLE 74 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN RUSSIA, THROUGH 2014 88

TABLE 75 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN RUSSIA, THROUGH 2014 89

REGIONAL PREVALENCE FORECASTS 89

CENTRAL AMERICA 89

Mexico, Belize, Nicaragua, Guatemala 89

TABLE 76   FORECAST EPIDEMIOLOGY: WET AMD IN CENTRAL AMERICA, THROUGH 2014 89

TABLE 77   FORECAST EPIDEMIOLOGY: DRY AMD IN CENTRAL AMERICA, THROUGH 2014 89

TABLE 78   FORECAST EPIDEMIOLOGY: GLAUCOMA IN CENTRAL AMERICA, THROUGH 2014 90

TABLE 79   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN CENTRAL AMERICA, THROUGH 2014 90

TABLE 80   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN CENTRAL AMERICA. THROUGH 2014 90

SOUTH AMERICA 91

Panama, Uruguay, Costa Rica, El Salvador, Honduras, Ecuador, Argentina, Paraguay, Chile, Venezuela, Peru, Bolivia, Colombia 91

TABLE 81   FORECAST EPIDEMIOLOGY: WET AMD IN SOUTH AMERICA, THROUGH 2014 91

TABLE 82   FORECAST EPIDEMIOLOGY: DRY AMD IN SOUTH AMERICA, THROUGH 2014 91

TABLE 83   FORECAST EPIDEMIOLOGY: GLAUCOMA IN SOUTH AMERICA, THROUGH 2014 91

TABLE 84   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN SOUTH AMERICA, THROUGH 2014 92

TABLE 85   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN SOUTH AMERICA, THROUGH 2014 92

CARIBBEAN 92

Jamaica, Dominican Republic, Cuba, Trinidad and Tobago, Haiti, and 10 other Countries Comprising less than 20% of the Region's Population 92

TABLE 86   FORECAST EPIDEMIOLOGY: WET AMD IN THE CARIBBEAN, THROUGH 2014 92

TABLE 87   FORECAST EPIDEMIOLOGY: DRY AMD IN THE CARIBBEAN, THROUGH 2014 93

TABLE 88   FORECAST EPIDEMIOLOGY: GLAUCOMA IN THE CARIBBEAN, THROUGH 2014 93

TABLE 89   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN THE CARIBBEAN THROUGH 2014 93

TABLE 90   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN THE CARIBBEAN, THROUGH 2014 94

NORTHERN EUROPE 94

Norway, Iceland, Finland, Denmark, Sweden 94

TABLE 91   FORECAST EPIDEMIOLOGY: WET AMD, NORTHERN EUROPE, THROUGH 2014 94

TABLE 92   FORECAST EPIDEMIOLOGY: DRY AMD, NORTHERN EUROPE, THROUGH 2014 94

TABLE 93   FORECAST EPIDEMIOLOGY: GLAUCOMA, NORTHERN EUROPE, THROUGH 2014 95

TABLE 94   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, NORTHERN EUROPE, THROUGH 2014 95

TABLE 95   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, NORTHERN EUROPE, THROUGH 2014 95

CENTRAL AND EASTERN EUROPE 96

Serbia, Liechtenstein, Estonia, Slovenia, Macedonia, Latvia, Albania, Lithuania, Bosnia and Herzegovina, Croatia, Georgia, Slovakia, Azerbaijan, Bulgaria, Belarus, Hungary, Czech Republic, Romania, Poland, Ukraine, Netherlands Antilles, Montenegro, Cyprus, Armenia, Turkmenistan 96

TABLE 96   FORECAST EPIDEMIOLOGY: WET AMD, CENTRAL AND EASTERN EUROPE, THROUGH 2014 96

TABLE 97   FORECAST EPIDEMIOLOGY: DRY AMD, CENTRAL AND EASTERN EUROPE, THROUGH 2014 96

TABLE 98   FORECAST EPIDEMIOLOGY: GLAUCOMA, CENTRAL AND EASTERN EUROPE, THROUGH 2014 96

TABLE 99   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, CENTRAL AND EASTERN EUROPE, THROUGH 2014 97

TABLE 100   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, CENTRAL AND EASTERN EUROPE, THROUGH 2014 97

AUSTRALIA 97

Australia, Guinea, New Zealand, Papua New Guinea, Pipeline Analysis 97

TABLE 101   FORECAST EPIDEMIOLOGY: WET AMD IN AUSTRALIA 97

TABLE 102   FORECAST EPIDEMIOLOGY: DRY AMD IN AUSTRALIA, THROUGH 2014 98

TABLE 103   FORECAST EPIDEMIOLOGY: GLAUCOMA IN AUSTRALIA, THROUGH 2014 98

TABLE 104   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN AUSTRALIA, THROUGH 2014 98

TABLE 105   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN AUSTRALIA, THROUGH 2014 99

ASIA-OTHER 99

Indonesia, Pakistan, Bangladesh, Philippines, Vietnam, Turkey, Thailand, South Korea, Burma, Nepal, Afghanistan, Uzbekistan, and 76 Other Countries Comprising 18% of the Region's Population 99

TABLE 106   FORECAST EPIDEMIOLOGY: WET AMD, ASIA-OTHER, THROUGH 2014 99

TABLE 107   FORECAST EPIDEMIOLOGY: DRY AMD, ASIA-OTHER, THROUGH 2014 99

TABLE 108   FORECAST EPIDEMIOLOGY: GLAUCOMA, ASIA-OTHER, THROUGH 2014 100

TABLE 109   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, ASIA-OTHER, THROUGH 2014 100

TABLE 110   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, ASIA-OTHER, THROUGH 2014 100

MIDDLE EAST 101

United Arab Emirates, Saudi Arabia, Israel, Gaza Strip, Kuwait, West Bank, Lebanon, Jordan, Syria, Yemen, Iraq, Iran 101

TABLE 111   FORECAST EPIDEMIOLOGY: WET AMD, MIDDLE EAST, THROUGH 2014 101

TABLE 112   FORECAST EPIDEMIOLOGY: DRY AMD, MIDDLE EAST, THROUGH 2014 101

TABLE 113   FORECAST EPIDEMIOLOGY: GLAUCOMA, MIDDLE EAST, THROUGH 2014 101

TABLE 114   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, MIDDLE EAST, THROUGH 2014 102

TABLE 115   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, MIDDLE EAST, THROUGH 2014 102

SOUTHERN AFRICA 102

South Africa, Cape Verde, Malawi, Swaziland, Botswana, Zambia, Angola, Zimbabwe 102

TABLE 116   FORECAST EPIDEMIOLOGY: WET AMD, SOUTHERN AFRICA, THROUGH 2014 102

TABLE 117   FORECAST EPIDEMIOLOGY: DRY AMD, SOUTHERN AFRICA, THROUGH 2014 103

TABLE 118   FORECAST EPIDEMIOLOGY: GLAUCOMA, SOUTHERN AFRICA, THROUGH 2014 103

TABLE 119   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, SOUTHERN AFRICA THROUGH 2014 103

TABLE 120   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, SOUTHERN AFRICA, THROUGH 2014 104

AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST 104

Chapter-7: PIPELINE ANALYSIS

TABLE 121 APPROVED PRODUCT SALES FORECAST, 2008-2014 ($ MILLIONS) 105

TABLE 122 PIPELINE SALES FORECAST, 2008-2014 ($ MILLIONS) 105

MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 106

STRINGENT REGULATORY PATHWAY EXISTS FOR DRY-EYE DISEASE 106

Sustained Delivery Is a Common Trait Among Leading Products in Development 106

Sustained Delivery …(Continued) 107

SiRNA Therapies in Development Experience Systemic Safety Concerns 108

2009 APPROVALS IN OPHTHALMOLOGY THERAPY 109

ACUVAIL 109

TABLE 123 SNAPSHOT OF ACUVAIL 110

Clinical Results 110

BEPREVE 110

TABLE 124 SNAPSHOT OF BEPREVE 111

Clinical Results 111

BESIVANCE 111

TABLE 125 SNAPSHOT OF BESIVANCE 112

OZURDEX 113

TABLE 126 SNAPSHOT OF OZURDEX 113

ZIRGAN 114

OPHTHALMIC DRUGS IN ADVANCED DEVELOPMENT 115

PHASE III 115

VEGF Trap-Eye 115

TABLE 127 SNAPSHOT OF VEGF TRAP-EYE 116

Clinical Results 116

Iluvien 117

TABLE 128 SNAPSHOT OF ILUVIEN 117

Clinical Results 117

Luveniq 118

TABLE 129 SNAPSHOT OF LUVENIQ 118

PHASE II 119

Ecabet 119

TABLE 130 SNAPSHOT OF ECABET 119

Clinical Results 119

Androgen Tears 120

TABLE 131 SNAPSHOT OF ANDROGEN TEARS 120

PIPELINE ANALYSIS BY COMPANY 121

TABLE 132 ALCON'S OPHTHALMIC PIPELINE 121

TABLE 133 ALLERGAN'S OPHTHALMIC PIPELINE 121

TABLE 134 PFIZER'S OPHTHALMIC PIPELINE 121

TABLE 135 NOVARTIS' OPHTHALMIC PIPELINE 122

TABLE 136 NOVARTIS' OPHTHALMIC PIPELINE 122

TABLE 137 MERCK OPHTHALMIC PIPELINE 122

TABLE 138 SANTEN OPHTHALMIC PIPELINE 123

Chapter-8: COMPANY PROFILES

SUMMARY 124

ABBOT MEDICAL PRODUCTS 125

Business Overview 125

Leading Products 125

Corporate Strategy 125

ACUCELA 125

Business Overview 125

Leading Products 126

Corporate Strategy 126

AERIE PHARMA 126

Business Overview 127

Leading Products 127

Corporate Strategy 127

AKORN, INC. 127

Business Overview 128

Leading Products 128

Akten 128

Timolol Maleate 128

Corporate Strategy 128

ALCON 129

Business Overview 129

Leading Products 129

Pataday 130

Vigamox 130

Nevanac 130

Triesence 130

Tobradex 130

Travatan and Travatan Z 130

Azopt 131

Azarga 131

Duotrav 131

Corporate Strategy 131

ALIMERA SCIENCES 131

Business Overview 132

Leading Products 132

Iluvien 132

Other Products 132

Corporate Strategy 132

ALLERGAN, INC. 133

Business Overview 133

Leading Products 133

Restasis and Others 133

Lumigan and Others 133

Corporate Strategy 134

CAN-FITE BIOPHARMA LTD. 134

Business Overview 135

Leading Products 135

Corporate Strategy 135

COMENTIS 135

Business Overview 136

Leading Products 136

ATG-3 136

Corporate Strategy 136

DANUBE PHARMACEUTICALS 136

Business Overview 137

Leading Products 137

DNB-001 137

Corporate Strategy 137

ESBATECH 137

Business Overview 137

Leading Products 138

ESBA105 138

Corporate Strategy 138

EYEGATE PHARMA 138

Business Overview 138

Leading Products 138

EGP-437 138

Corporate Strategy 139

GENENTECH 139

Business Overview 139

Leading Products 139

Lucentis 139

Avastin (Bevacizumab) 140

Corporate Strategy 140

GENE SIGNAL 141

Business Overview 141

Leading Products 141

GS-101 141

Corporate Strategy 141

ICO THERAPEUTICS 142

Business Overview 142

Leading Products 142

Corporate Strategy 142

INSITE VISION 143

Business Overview 143

Leading Products 143

AzaSite 143

Corporate Strategy 143

INSPIRE PHARMACEUTICALS, INC 143

Business Overview 144

Leading Products 144

Prolacria (diquafosol tetrasodium) 144

Additional Products 144

Corporate Strategy 145

IRIDEX 145

Business Overview 145

Leading Products 145

Transpupillary Thermotherapy 145

Corporate Strategy 146

ISTA PHARMACEUTICALS 146

Business Overview 146

Leading Products 146

Bepreve 146

Xibrom 147

Istalol 147

Corporate Strategy 147

JERINI AG 147

Business Overview 147

Leading Products 148

a5ß1 Integrin (JSM 6427) 148

Corporate Strategy 148

LPATH INCORPORATED 148

Business Overview 148

Leading Products 148

ISONEP 148

Corporate Strategy 149

LUX BIOSCIENCES 149

Business Overview 149

Leading Products 149

Luveniq 149

Corporate Strategy 150

MACUSIGHT 150

Website: www.macusight.com/ 150

Business Overview 150

Leading Products 151

Perceiva 151

Corporate Strategy 151

MERCK 151

Business Overview 151

Leading Products 151

Intraocular pressure therapies 151

Corporate Strategy 152

NEUROTECH 152

Business Overview 152

Leading Products 153

Company Strategy 153

NICOX S.A. 153

Business Overview 153

Leading Products 154

NCX 116 154

Corporate Strategy 154

NOVARTIS 154

Business Overview 154

Leading Products 155

Lucentis 155

Visudyne 155

Company Strategy 155

OPKO HEALTH 155

Business Overview 155

Leading Products 156

Bevasiranib 156

Civamide 156

Doxovir 156

Company Strategy 157

OSI PHARMACEUTICALS 157

Business Overview 157

Leading Products 157

Macugen 157

Corporate Strategy 158

OTHERA 158

Business Overview 158

Leading Products 158

Corporate Strategy 159

Business Overview 159

Leading Products 159

Zybrestat 159

Corporate Strategy 159

PFIZER 160

Business Overview 160

Leading Products 160

Xalatan (latanoprost. ophthalmic solution) 160

Corporate Strategy 160

POTENTIA PHARMACEUTICALS 161

Business Overview 161

Leading Products 161

POT-4 161

Corporate Strategy 161

QLT INC. 161

Business Overview 162

Leading Products 162

Visudyne 162

Corporate Strategy 162

PSIVIDA CORPORATION 163

Business Overview 163

Leading Products 163

Iluvien 163

Retisert 163

Corporate Strategy 163

QUARK BIOTECH 164

Business Overview 164

Leading Products 164

PF-4523655 164

Corporate Strategy 164

REGENERON 165

Business Overview 165

Leading Products 165

VEGF-Trap Eye 165

Corporate Strategy 165

SANOFI-AVENTIS 166

Business Overview 166

Leading Products 166

Prednisporin 166

FOV2302 166

Corporate Strategy 167

SANTEN SEIYAKU 167

Business Overview 167

Leading Products 168

Hyalein 168

Cravit/Oftaquix 168

Corporate Strategy 168

SANWA KAGAKU KENKYUSHO CO., LTD 168

Business Overview 168

Leading Products 168

Corporate Strategy 169

SIRION THERAPEUTICS 169

Business Overview 169

Leading Products 169

Durezol 169

Zirgan 169

Corporate Strategy 170

TARGEGEN 170

Business Overview 170

Leading Products 170

TG100801 170

THROMBOGENICS 171

Business Overview 171

Leading Products 171

Microplasmin 171

Corporate Strategy 171

VITREORETINAL TECHNOLOGIES 172

Business Overview 172

Leading Products 172

Vitreosolve 172

Corporate Strategy 172

LEADING UNITED STATES EYE RESEARCH CENTERS 172

MASSACHUSETTS EYE & EAR INFIRMARY 172

Summary 173

BASCOM PALMER EYE INSTITUTE 173

Summary 173

DOHENY EYE INSTITUTE 173

Summary 173

JULES STEIN EYE INSTITUTE 173

Summary 174

THE CULLEN EYE INSTITUTE – BAYLOR COLLEGE OF MEDICINE 174

Summary 174

THE WILMER EYE INSTITUTE AT JOHNS HOPKINS HOSPITAL 174

Summary 174

WILLS EYE HOSPITAL 174

Summary 174

CLAY COUNTY HOSPITAL 175

Summary 175

FORT LAUDERDALE EYE INSTITUTE 175

Summary 175

PHILLIPS EYE INSTITUTE 175

Summary 175

SELECTED GLOBAL EYE HOSPITALS 176

INDIA 176

Aravind Eye Hospital in India 176

Summary 176

Al-Shifa Hospital 176

Summary 176

CHINA 176

He Eye Hospital 176

Summary 177

To order this report:

Drug and Medication Industry: Ophthalmic Therapeutic Drugs: Technologies and Global Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.